First-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer.
Professor David Kerr warns against 'treating the marker' in CRC. Should rising ctDNA trigger chemo without radiologic proof?
Diagnosis of stomach cancer (also known as gastric cancer) is now occurring more often at earlier stages, likely related to advances in tests and imaging. Importantly, stomach cancer is also being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results